Company profile
Eastgate Biotech Corp.
OTC: ETBI · Healthcare · Medical - Pharmaceuticals
PublicHQ Toronto, NVCIK 0001099574Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 35
v0.1 · 5/100 weight · pillars only
↑ listing tenure, market scale · ↓ filing timeliness, workforce scale
Methodology →Revenue TTM
$44.1k
Rev growth YoY (TTM)
-53.0%
Net income (FY)
-$3.0M
Employees
2
as of 2026-09-21
Market cap
$5.6M
as of 2026-09-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$3.0M-$3.0M2016
Operating income-$2.6M-$2.6M2016
Total assets$0$02016
Liabilities$4.6M$4.6M2016
Equity-$4.6M-$4.6M2016
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Eastgate Biotech Corp.’s financial profile?
Eastgate Biotech Corp. earned -$3.0M in FY2016 net income.
Peers · Healthcare
CalciMedica, Inc.——Cardiac Biotech Solutions Inc.——Acurx Pharmaceuticals, Inc.——Univec, Inc.——Kairos Pharma, Ltd.——Liminatus Pharma, Inc. Class A Common Stock——Key facts
CEORosella C. Perri
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersToronto, NV
ExchangeOTC: ETBI
Employees2
IPO date2014-03-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.